After puberty, you have a set number of muscle cells, and all you are able to do is increase the size of these cells.
Changchun, China (PRWEB) May 13, 2006
Researchers at Neogenica BioScience Ltd. have released Revitropin to the public. Revitropin is a drug that is most notable for its ability to enhance one’s physique.
According to researchers, “After puberty, you have a set number of muscle cells, and all you are able to do is increase the size of these cells.” Revitropin causes hyperplasia, which allows your body to increase its number of muscle cells. The more muscle cells you have, the easier it is to increase muscle size and density. For this reason, Revitropin enables one to change their genetic abilities.
This is of great benefit in the area of body building. With Revitropin, the only weight you gain is from lean muscle tissue. “You can expect to gain one to two pounds of new lean muscle every two to three weeks.” Revitropin also promotes fat loss. This allows for heavy food intake during body building periods without unwanted weight gain. Additionally, it increases the size and number of one’s veins.
Revitropin’s effects include “increased amino acid transport to cells, increased glucose transport, increased protein synthesis, decreased protein degradation, and increased RNA synthesis.” This means that your muscles absorb more protein, and your cells are forced to burn off fat for energy.
Some have compared the effects of Revitropin to that of growth hormone. While both are similar, Revitropin is more effective at directly causing muscle growth, and it is much less expensive.
Because Revitropin is still being researched by the FDA for its benefits toward medical patients who have suffered nerve and muscle damage, it is only available to a select few pharmaceutical companies for research purposes.
China-based Neogenica Bioscience Ltd. is a registered pharmaceutical company that specializes in researching growth and development. To learn more about Revitropin, visit their website at http://www.revitropin.com.
Neogenica BioScience Ltd.
+386 31 560488